Multiple inflammatory diseases are characterized by dysregulation of tumor necrosis factor alpha (TNFα), and the development of anti-TNFα inhibitors has been a milestone in the treatment of rheumatoid arthritis (RA), inflammatory bowel disease, ankylosing spondylitis, and psoriatic arthritis. This evidence concerns the gene TNF and inflammatory bowel disease.